Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 601–700 of 1,000

Synthetic lethality in lung cancer and translation to clinical therapies
Ada W.Y. Leung, Tanya de Silva, Marcel B. Bally, William Wirt Lockwood · 2016 · Molecular Cancer
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
Yoshitaro Shindo, Shoichi Hazama, Nobuaki Suzuki, Haruo Iguchi, Kazuhiro Uesugi, Hiroaki Tanaka, Atsushi Aruga, Takashi Hatori, Hidenobu Ishizaki, Yuzo Umeda et al. · 2017 · Journal of Experimental & Clinical Cancer Research
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli · 2017 · Translational Lung Cancer Research
T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1
Haichuan Zhu, Liuzhen Zhang, Yilin Wu, Bingjie Dong, Weilong Guo, Mei Wang, Lu Yang, Xiaoying Fan, Yuliang Tang, Ningshu Liu et al. · 2018 · eLife
Hyperprogressive Disease in Hepatocellular Carcinoma with Immune Checkpoint Inhibitor Use: A Case Series
Daniel Jiahao Wong, Joycelyn Jie Xin Lee, Su Pin Choo, Choon Hua Thng, Tiffany Priyanthi Hennedige · 2019 · Immunotherapy
Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
Liling Wen, Huanzi Lu, Qiusheng Li, Qunxing Li, Shuqiong Wen, Dikan Wang, Xi Wang, Juan Fang, Jun Cui, Bin Cheng et al. · 2019 · Journal of Experimental & Clinical Cancer Research
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Ying Yang, Yongfeng Yu, Shun Lü · 2020 · Science China Life Sciences
Update of early phase clinical trials in cancer immunotherapy
Dae Ho Lee · 2021 · BMB Reports
Immune classification of clear cell renal cell carcinoma
Sumeyye Su, Shaya Akbarinejad, Leili Shahriyari · 2021 · Scientific Reports
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Pan Shen, Liang Han, Xin Ba, Kai Qin, Shenghao Tu · 2021 · Frontiers in Pharmacology
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia, Weiwei Tang · 2021 · Frontiers in Oncology
Presence of Tim 3+ and PD ‐1+ CD8 + T cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features
Max Klapholz, Michael G. Drage, Amitabh Srivastava, Ana Carrizosa Anderson · 2022 · The Journal of Pathology
Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy
Wei Hao Xiong, Zhengdong Guo, Baoyan Zeng, Teng Wang, Xiaowei Zeng, Wei Cao, Daizheng Lian · 2022 · Frontiers in Bioengineering and Biotechnology
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Adriana Agnese Amaro, Francesco Reggiani, Daniela Fenoglio, Rosaria M. R. Gangemi, Anna Tosi, Alessia Parodi, Barbara Banelli, Valentina Rigo, Luca Mastracci, Federica Grillo et al. · 2023 · Journal of Experimental & Clinical Cancer Research
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Rachel S. Goodman, Seungyeon Jung, Justin Micah Balko, Douglas Buckner Johnson · 2023 · Immunological Reviews
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas
Zenghui Qian, Yiming Li, Xing Fan, Chuanbao Zhang, Yinyan Wang, Tao Jiang, Xing Liu · 2018 · OncoImmunology
sLAG-3 in non-small-cell lung cancer patients’ serum
Yayi He, Yan Wang, Sa Zhao, Chao Zhao, Caicun Zhou, Fred R. Hirsch · 2018 · OncoTargets and Therapy
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
Zhi Ji, Zhi Peng, Jifang Gong, Xiaotian Zhang, Jian Li, Ming Shian Lu, Zhihao Lü, Lin Shen · 2019 · BMC Cancer
Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape
Malte Mohme, Cécile L. Maire, Simon Schliffke, Simon Andreas Joosse, Malik Alawi, Jakob Matschke, Ulrich Schüller, Judith Dierlamm, Tobias Martens, Klaus Pantel et al. · 2020 · Acta Neuropathologica Communications
Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
Yan Chen, Junjie Hu, Fangfang Bu, Haiping Zhang, Ke Fei, Peng Zhang · 2020 · BMC Cancer
Immune classification of osteosarcoma
Le, Trang, Department of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA MA 01003-9305, USA, Su, Sumeyye, Shahriyari, Leili · 2021 · Mathematical Biosciences and Engineering
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
Lucas Vieira dos Santos, Carina Meira Abrahão, William N. William · 2021 · Frontiers in Oncology
Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
Rasa Islam, Aleta Pupovac, Vera J. Evtimov, Nicholas R. Boyd, Runzhe Shu, Richard L. Boyd, Alan O. Trounson · 2021 · Cells
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Sanjay Chandrasekaran, Christopher Ronald Funk, Troy J. Kleber, Chrystal Mary Paulos, Mala Shanmugam, Edmund K. Waller · 2021 · Frontiers in Immunology
Immunotherapy Resistance in Glioblastoma
Wang, Elaina J., Chen, Jia-Shu, Jain, Saket, Morshed, Ramin A., Haddad, Alexander F., Gill, Sabraj, Beniwal, Angad S., Aghi, Manish K. · 2021 · Frontiers in Genetics
HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer
Yifei Cheng, Lu Li, Xiyi Wei, Fan Xu, Xiaochen Huang, Feng Qi, Yanyan Zhang, Xiao Li · 2023 · Cancer Science
The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer
Basma Zohair, Dounia Chraa, Ibtissam Rezouki, Hamza Benthami, Ibtissam Razzouki, Mohamed Elkarroumi, Daniel Olive, Mehdi Karkouri, Abdallah Badou · 2023 · Frontiers in Immunology
Immune checkpoint inhibitors in infectious disease
Hannah A. D. King, Sharon R. Lewin · 2024 · Immunological Reviews
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
Ri‐Yao Yang, Mien‐Chie Hung · 2017 · Science China Life Sciences
Therapeutic Development of Immune Checkpoint Inhibitors
Jilin Wang, Teddy Yang, Jie Xu · 2020 · Advances in experimental medicine and biology
The TLR4/ERK/PD‑L1 axis may contribute to NSCLC initiation
Xiuhua Kang, Penghui Li, Chuibin Zhang, Yunshan Zhao, Huoli Hu, Guilan Wen · 2020 · International Journal of Oncology
Roles for the FCRL6 Immunoreceptor in Tumor Immunology
Randall S. Davis · 2020 · Frontiers in Immunology
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
Marina C. Martinez, Soyeon Kim, Naomi Saint Jean, Shaun O’Brien, Lurong Lian, Jing Sun, Raluca I. Verona, Edmund K. Moon · 2021 · OncoImmunology
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
Xiuman Zhou, Ling Jiao, Yuzhen Qian, Qingyu Dong, Yixuan Sun, Wei Zheng, Wenshan Zhao, Wenjie Zhai, Lu Qiu, Yahong Wu et al. · 2021 · Biomolecules
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
Alexander Chi, Xia He, Lin Hou, Nam Phong Nguyen, Guangying Zhu, Robert Bruce Cameron, Jay M. Lee · 2021 · Cancers
Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)
Tyson A. Rietz, Kevin B. Teuscher, Jonathan J. Mills, Rocco D. Gogliotti, Lance T. Lepovitz, William R. Scaggs, Keisuke Yoshida, Kelvin Luong, Taekyu Lee, Stephen W. Fesik · 2021 · Journal of Medicinal Chemistry
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
Shalin Jyotindra Shah, Kevin Wood, Brian William Labadie, Brian M. Won, Ryan J. Brisson, Theodore G Karrison, Thomas A. Hensing, Mark F. Kozloff, Riyue Bao, Jyoti D. Patel et al. · 2017 · Oncotarget
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
Yayi He, Sangtian Liu, Jane Mattei, Paul A. Bunn, Caicun Zhou, Daniel C. F. Chan · 2018 · Drug Design Development and Therapy
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi · 2022 · Life Sciences
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer
Guan-Yu Xiao, Xiaochao Tan, B. Leticia Rodriguez, Don Lynn Gibbons, Shike Wang, Chao‐Liang Wu, Xin Liu, Yu Yan Jiang, Mayra E. Vasquez, Hai Thanh Tran et al. · 2023 · Proceedings of the National Academy of Sciences
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Junghwa Lee, Eui Ho Kim · 2023 · Frontiers in Oncology
Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma
Hang Su, Huikang Xie, Chenyang Dai, Yijiu Ren, Yunlang She, Long Xu, Donglai Chen, Dong Xie, Liping Zhang, Gening Jiang et al. · 2018 · Lung Cancer
Increased serum levels of Galectin‑9 in patients with chronic lymphocytic leukemia
Kamil Wdowiak, Enrique Gallego-Colón, Tomasz Francuz, Paulina Czajka‐Francuz, Natalia Ruiz‐Agamez, Marcin Kubeczko, Iga Grochoła, Maciej Tomasz Wybraniec, Jerzy Tadeusz Chudek, Jerzy Wojnar · 2018 · Oncology Letters
LNK suppresses interferon signaling in melanoma
Ling‐Wen Ding, Qiao‐Yang Sun, Jarem J. Edwards, Lucia Torres Fernández, Xue‐Bin Ran, Siqin Zhou, Richard A. Scolyer, James S. Wilmott, John F. Thompson, Ngan Doan et al. · 2019 · Nature Communications
Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes.
Chong Zhang, Louise de A F Fonseca, Zhen-Wei Shi, Cheng Zhu, A. Dekker, I. Bermejo, L. Wee · 2020 · Methods
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano et al. · 2021 · BMC Cancer
Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients
Mohammad A. Al-Mterin, Alhasan Alsalman, Eyad Elkord · 2022 · Frontiers in Immunology
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system
Giulia Grizzi, Mario Caccese, Αναστάσιος Γκουντάκος, Luisa Carbognin, Giampaolo Tortora, Emilio Bria, Sara Pilotto · 2017 · Expert Review of Molecular Diagnostics
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
Miles Cameron Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer Ann Wargo · 2018 · Frontiers in Immunology
Unmasking PD-1 Resistance by Next-Generation Sequencing
Carlo Bruno Bifulco, Walter John Urba · 2016 · New England Journal of Medicine
FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression
Atsushi Okato, Takanobu Utsumi, Michela Ranieri, Xingnan Zheng, Mi Zhou, Luiza Doro Pereira, Ting Chen, Yuki Kita, Di Wu, Hyesun Hyun et al. · 2024 · Journal of Clinical Investigation
Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
Andrew Meci, Neerav Goyal, Guy Slonimsky · 2024 · Cancers
Phototherapeutic nanoagents for cancer immunotherapy
Maomao He, M. Xiao, Ran Wang, Jiangli Fan, Xiaojun Peng, Wen Ce Sun · 2024 · Progress in Materials Science
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study
Dongjiang Chen, Son B Le, Ashley Parham Ghiaseddin, Harshit Manektalia, Ming Li, Adam O’Dell, Maryam Rahman, David Dinh Tran · 2025 · Med
Cancer Evolution during Immunotherapy
Miles Cameron Andrews, Jennifer Ann Wargo · 2017 · Cell
Microbiome and Cancers, With Focus on Genitourinary Tumors
Alessia Cimadamore, Matteo Santoni, Francesco Massari, Silvia Gasparrini, Liang Cheng C, Antonio Lopez-beltran B, Rodolfo Montironi, Marina Scarpelli · 2019 · Frontiers in Oncology
Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma
Kuan‐Yu Wang, Ruoyu Huang, Xuezhi Tong, Kenan Zhang, Yanwei Liu, Fan Zeng, Huimin Hu, Tao Jiang · 2019 · CNS Neuroscience & Therapeutics
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD ‐(L)1 therapy: Updated
Keywan Mortezaee, Jamal Majidpoor · 2023 · Journal of Cellular and Molecular Medicine
Immunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, Nicolas, Hottinger, Andreas Felix · 2021 · Cancers
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
Yun Yu Hu, Sébastien Paris, Narayan Sahoo, Genevieve Bertolet, Qi Wang, Qianxia Wang, Hampartsoum B. Barsoumian, Jordan DA SILVA, Ailing Huang, Denaha J. Doss et al. · 2023 · JCI Insight
Drug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma
Yingying Shao, Ranran Su, Yu Wang, Shuangshuang Yin, Weiling Pu, Sangho Koo, Haiyang Yu · 2023 · Acupuncture and Herbal Medicine
Current state of immune checkpoints therapy for glioblastoma
He Wang, Jing Yang, Xiangjun Li, Zhao Hai · 2024 · Heliyon
Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells
Nina Chi-Sabins, Benjamin C. Harman, Linda R. Barone, Shixue Shen, Sandra Santulli-Marotto · 2016 · Frontiers in Immunology
Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
Hazem Edmond El-Osta, Kamran Shahid, Glenn Morris Mills, Prakash Peddi · 2016 · OncoTargets and Therapy
Immune checkpoint receptors in cancer: redundant by design?
Jing Li, Ling Ni, Chen Dong · 2017 · Current Opinion in Immunology
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
Nicolas Jacquelot, Jonathan M. Pitt, David Pierre Enot, María Paula Roberti, Connie P.M. Duong, Sylvie Rusakiewicz, Alexander M.M. Eggermont, Laurence Zitvogel · 2017 · OncoImmunology
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
Thomas B. Powles, Andrea Necchi, Galit P. Rosen, Subramanian Hariharan, Andrea Borghese Apolo · 2017 · Clinical Genitourinary Cancer
A four-hypoxia-genes-based prognostic signature for oral squamous cell carcinoma
Chenguang Zhao, Yingrui Zhou, Hongwei Ma, Jinhui Wang, Haoliang Guo, Hao Liu · 2021 · BMC Oral Health
TIM3+ cells in gastric cancer: clinical correlates and association with immune context
Ke Chen, Yun Gu, Yifan Cao, Hanji Fang, Kunpeng Lv, Xin Liu, Xudong He, Jieti Wang, Chao Lin, Hao Liu et al. · 2021 · British Journal of Cancer
XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8+ T cells
Jing Li, Liyan Che, Chang Xu, Dongdong Lu, Yan Xu, Mengru Liu, Wenshu Chai · 2022 · Journal of Receptors and Signal Transduction
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Dongzhu Liu, Shan Gao, Yujia Zhai, Xiaoye Yang, Guangxi Zhai · 2022 · International Journal of Pharmaceutics
Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
Li-ping Zhao, Jun-hu Hu, Die Hu, Haojie Wang, Chang-gang Huang, Ruhua Luo, Xin‐Yun Huang, Xin‐Yun Huang, Tian Xie, Jian-Shu Lou · 2022 · Biomedicine & Pharmacotherapy
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Alice Tzeng, Claudia Marcela Diaz-Montero, Patricia A. Rayman, Jin S. Kim, Paul G. Pavicic, James Harold Finke, Pedro Coelho Barata, Marcelo Lamenza, Sarah Devonshire, Kim Schach et al. · 2018 · Targeted Oncology
Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities
Minhong Shen, Yibin Kang · 2020 · Genes & Development
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Rachel Su Jen Wong, Rebecca Jia Min Ong, Joline SJ Lim · 2023 · Cancer Drug Resistance
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Ginette S. Santiago-Sánchez, Kellsye P. Fabian, James W. Hodge · 2024 · Cancer Biology & Therapy
Immunotherapy for hepatocellular carcinoma
Xiaoxia Wang, Jun Lu · 2024 · Chinese Medical Journal
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes
Ornella Franzese · 2024 · International Journal of Molecular Sciences
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
Barbara Castella, Myriam Foglietta, Chiara Riganti, Massimo Massaia · 2018 · Frontiers in Immunology
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
Jessica Marie Konen, B. Leticia Rodriguez, Jared J. Fradette, Laura Gibson, Denali H. Davis, Rosalba Minelli, Michael D. Peoples, Jeffrey J. Kovacs, Alessandro Carugo, Christopher Aaron Bristow et al. · 2019 · Cancers
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer
Jane D. Robertson, Max Salm, Markus Dangl · 2019 · Immuno-Oncology Technology
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Maria Tampaki, Evangelos Ionas, Emilia S. Hadziyannis, Melanie J. Deutsch, Katerina S. Malagari, John S. Koskinas · 2020 · Cancers
ImmunoPET Imaging of TIM‐3 in Murine Melanoma Models
Weijun Wei, Dawei Jiang, Hye Jin Lee, Jonathan W. Engle, Hisaya Akiba, Jianjun Liu, Weibo Cai · 2020 · Advanced Therapeutics
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Josephine Tsang, Jeffrey Sum Lung Wong, Gin Wai Kwok, Bryan Cho Wing Li, Roland Ching-Yu Leung, Joanne Wing Yan Chiu, Tan To Cheung, Thomas C. C. Yau · 2021 · Expert Review of Gastroenterology & Hepatology
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
Xianbin Kong, Peng Lü, Chuanxin Liu, Yuzhu Guo, Yuying Yang, Yingying Peng, Fangyuan Wang, Bo Zhang, Xiaoxin Dou, Haoyang Shi et al. · 2021 · Molecular Medicine Reports
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Muhammad Sadeqi Nezhad, Mahboubeh Yazdanifar, Meghdad Abdollahpour‐Alitappeh, Arash Sattari, Alexander Marcus Seifalian, Nader Bagheri · 2021 · Biotechnology and Bioengineering
Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer
Matteo Bellone, Angela Rita Elia · 2017 · Cytokine & Growth Factor Reviews
TIM-3 Expression and M2 Polarization of Macrophages in the TGFβ-Activated Tumor Microenvironment in Colorectal Cancer
Masanori Katagata, Hirokazu Okayama, Shotaro Nakajima, Katsuharu Saito, Takahiro Sato, Mei Sakuma, Satoshi Fukai, Eisei Endo, Wataru Sakamoto, Motonobu Saito et al. · 2023 · Cancers
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Angela Rita Elia, Sara Caputo, Matteo Bellone · 2018 · Frontiers in Immunology
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
Hao Xu, Songshan Chai, Yihao Wang, Jiajing Wang, Dongdong Xiao, Junjun Li, Nanxiang Xiong · 2020 · CNS Neuroscience & Therapeutics
Carbon Dioxide Conversion with High-Performance Photocatalysis into Methanol on NiSe2/WSe2
Zheng Luo, Yinghan Li, Fengbo Guo, Kaizhi Zhang, Kankan Liu, Wanli Jia, Yuxia Zhao, Yan Jie Sun · 2020 · Energies
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer
Sara Samir Foad Al-Badran, Lauren Grant, Maejoy V Campo, Jitwadee Inthagard, Kathryn A.F. Pennel, Jean A. Quinn, Prakash Konanahalli, Liam Hayman, Paul G. Horgan, Donald McMillan et al. · 2020 · The Journal of Pathology Clinical Research
IFN-γ and CD38 in Hyperprogressive Cancer Development
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier‐Luigi Lollini, Arianna Palladini · 2021 · Cancers
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy
Genevieve Elizabeth Martin, Debattama R. Sen, Matthew J. Pace, Nicola Robinson, Jodi Meyerowitz, Emily Adland, John Patrick Thornhill, Mathew Jones, Ane Ogbe, Lucia Parolini et al. · 2021 · Frontiers in Immunology
The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook
Zhou Zhou, Yuhao Hu, Yixuan Wu, Qianyi Qi, Jianxin Wang, Lin Chen, Feng Wang · 2022 · Molecular Immunology
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, Wenjuan, Marti, Thomas M., Dorn, Patrick, Peng, Ren-Wang · 2022 · Frontiers in Oncology
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects
Katsushige Kawase, Shusuke Kawashima, Joji Nagasaki, Takashi Inozume, Etsuko Tanji, Masahito Kawazu, Toyoyuki Hanazawa, Yosuke Togashi · 2023 · Cancer Immunology Research
T cell exhaustion drives osteosarcoma pathogenesis
Sun, Cheng-Ying, Zhang, Zhe, Tao, Lei, Xu, Fei-Fei, Li, Hui-Yuan, Zhang, Hui-Yu, Liu, Wei · 2021 · Annals of Translational Medicine
3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment
Zhanyi Zhang, Xuebo Chen, Sujie Gao, Xuedong Fang, Shengnan Ren · 2024 · Cellular Oncology
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Léa Berland, Zeina Gabr, Michelle Chang, Marius Ilié, Véronique Hofman, Guylène Rignol, François Ghiringhelli, Baharia Mograbi, Mohamad Rashidian, Paul M Hofman · 2024 · Frontiers in Immunology